BACKGROUND: We evaluated the association of pre-diagnostic plasma concentration of C-reactive protein, a sensitive, but non-specific indicator of inflammation, with subsequent risk of prostate cancer. METHODS: Included were 264 histologically confirmed prostate cancer cases and 264 age-matched controls who were participants in the CLUE II cohort of Washington County, MD. C-reactive protein was measured using a high-sensitivity immunoturbidimetric assay. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated from conditional logistic regression models by fourth of the C-reactive protein distribution with cutpoints based on the controls. The median concentrations from the lowest to highest fourth were 0.41, 1.03, 1.90, and 4.53 mg/L. RESULTS: Geometric mean plasma concentrations did not differ between the cases (1.24 +/- 2.94 mg/L) and controls (1.41 +/- 2.97 mg/L; P = 0.16). Compared to the bottom fourth, the ORs (95% CI) of prostate cancer were 1.29 (0.80-2.08), 0.98 (0.61-1.58), and 0.95 (0.57-1.58) for the second, third, and highest fourths (P trend = 0.66). These findings were unchanged after adjusting for body mass index (BMI) and cigarette smoking status or after excluding men with markedly elevated C-reactive protein, cases diagnosed during the first 2 years of follow-up, or controls who never had a PSA test. These findings did not differ by stage or grade of prostate cancer. CONCLUSIONS: Pre-diagnostic plasma concentration of C-reactive protein was not associated with subsequent risk of prostate cancer. Copyright 2004 Wiley-Liss, Inc.
BACKGROUND: We evaluated the association of pre-diagnostic plasma concentration of C-reactive protein, a sensitive, but non-specific indicator of inflammation, with subsequent risk of prostate cancer. METHODS: Included were 264 histologically confirmed prostate cancer cases and 264 age-matched controls who were participants in the CLUE II cohort of Washington County, MD. C-reactive protein was measured using a high-sensitivity immunoturbidimetric assay. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated from conditional logistic regression models by fourth of the C-reactive protein distribution with cutpoints based on the controls. The median concentrations from the lowest to highest fourth were 0.41, 1.03, 1.90, and 4.53 mg/L. RESULTS: Geometric mean plasma concentrations did not differ between the cases (1.24 +/- 2.94 mg/L) and controls (1.41 +/- 2.97 mg/L; P = 0.16). Compared to the bottom fourth, the ORs (95% CI) of prostate cancer were 1.29 (0.80-2.08), 0.98 (0.61-1.58), and 0.95 (0.57-1.58) for the second, third, and highest fourths (P trend = 0.66). These findings were unchanged after adjusting for body mass index (BMI) and cigarette smoking status or after excluding men with markedly elevated C-reactive protein, cases diagnosed during the first 2 years of follow-up, or controls who never had a PSA test. These findings did not differ by stage or grade of prostate cancer. CONCLUSIONS: Pre-diagnostic plasma concentration of C-reactive protein was not associated with subsequent risk of prostate cancer. Copyright 2004 Wiley-Liss, Inc.
Authors: Brandon L Pierce; Mary L Biggs; Marvalyn DeCambre; Alexander P Reiner; Christopher Li; Annette Fitzpatrick; Christopher S Carlson; Janet L Stanford; Melissa A Austin Journal: Cancer Causes Control Date: 2009-03-08 Impact factor: 2.506
Authors: Sarah C Markt; Jennifer R Rider; Kathryn L Penney; Fredrick R Schumacher; Mara M Epstein; Katja Fall; Howard D Sesso; Meir J Stampfer; Lorelei A Mucci Journal: Prostate Date: 2014-05-20 Impact factor: 4.104
Authors: Jennifer Rider Stark; Haojie Li; Peter Kraft; Tobias Kurth; Edward L Giovannucci; Meir J Stampfer; Jing Ma; Lorelei A Mucci Journal: Int J Cancer Date: 2009-06-01 Impact factor: 7.396
Authors: Luisa Zuccolo; Ross Harris; David Gunnell; Steven Oliver; Jane Athene Lane; Michael Davis; Jenny Donovan; David Neal; Freddie Hamdy; Rebecca Beynon; Jelena Savovic; Richard Michael Martin Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-09 Impact factor: 4.254
Authors: Ming-Hsi Wang; Kathy J Helzlsouer; Michael W Smith; Judith A Hoffman-Bolton; Sandra L Clipp; Viktoriya Grinberg; Angelo M De Marzo; William B Isaacs; Charles G Drake; Yin Yao Shugart; Elizabeth A Platz Journal: Prostate Date: 2009-06-01 Impact factor: 4.104
Authors: Anna E Prizment; Aaron R Folsom; Jill Dreyfus; Kristin E Anderson; Kala Visvanathan; Corinne E Joshu; Elizabeth A Platz; James S Pankow Journal: Cancer Causes Control Date: 2013-09-14 Impact factor: 2.506